Nitrate therapy for stable angina pectoris

New England Journal of Medicine

Volumn 338, Issue 8, 1998, Pages 520-531

  Parker, John D ^a   Parker, John O ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NITRATE;

ANGINA PECTORIS; CORONARY ARTERY DISEASE; DRUG HALF LIFE; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOTENSION; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBLINGUAL DRUG ADMINISTRATION; SYNCOPE; TRANSDERMAL DRUG ADMINISTRATION; TREATMENT INDICATION; TREATMENT PLANNING;

ANGINA PECTORIS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HUMANS; ISOSORBIDE DINITRATE; NITRATES; NITROGLYCERIN; VASODILATOR AGENTS;

EID: 0032545984     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199802193380807     Document Type: Review

References (97)

1. Murrell W. Nitroglycerine as a remedy for angina pectoris. Lancet 1879; 1:80-1, 113-5, 151-2, 225-7.
2. Stewart DD. Remarkable tolerance to nitroglycerine. Polyclinic 1888;6: 43.
3. Bogaert MG, De Schaepdryver AF. Tolerance towards glyceryl trinitrate (trinitrin) in dogs. Arch Int Pharmacodyn Ther 1968;171:221-4.
4. Torfgard KE, Ahlner J. Mechanisms of action of nitrates. Cardiovasc Drugs Ther 1991;8:701-17.
5. Murad F. Drugs used for the treatment of angina: organic nitrates, calcium-channel blockers, and β-adrenergic antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis, of therapeutics. 8th ed. New York: Pergamon Press, 1990: 764-83.
6. Bogaert MG. Pharmacokinetics of organic nitrates in man: an overview. Eur Heart J 1988;9:Suppl A:33-7.
7. Armstrong PW, Moffat JA, Marks GS. Arterial-venous nitroglycerin gradient during intravenous infusion in man. Circulation 1982;66:1273-6.
8. Needleman P, Lang S, Johnson EM Jr. Organic nitrates: relationship between biotransformation and rational angina pectoris therapy. J Pharmacol Exp Ther 1972;181:489-97.
9. Glancy DL, Richter MA, Ellis EV, Johnson W. Effect of swallowed isosorbide dinitrate on blood pressure, heart rate and exercise capacity in patients with coronary artery disease. Am J Med 1977;62:39-46.
10. Thadani U, Fung H-L, Darke AC, Parker JO. Oral isosorbide dinitrate in the treatment of angina pectoris: dose-response relationship and duration of action during acute therapy. Circulation 1980;62:491-502.
11. Idem. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. Am J Cardiol 1982;49:411-9.
12. Katsuki S, Murad F. Regulation of adenosine cyclic 3′,5′-monophosphate and guanosine cyclic 3′,5′-monophosphate levels and contractility in bovine tracheal smooth muscle. Mol Pharmacol 1977;13:330-41.
13. Axelsson KL, Wikberg JES, Andersson RGG. Relationship between nitroglycerin, cyclic GMP and relaxation of vascular smooth muscle. Life Sci 1979;24:1779-86.
14. Fung HL, Chung SJ, Bauer JA, Chong S, Kowaluk EA. Biochemical mechanism of organic nitrate action. Am J Cardiol 1992;70:4B-10B.
15. Harrison DG, Bates JN. The nitrovasodilators: new ideas about old drugs. Circulation 1993;87:1461-7.
16. Needleman P, Jakschik B, Johnson EM Jr. Sulthydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther 1973;187: 324-31.
17. Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitroprusside and nitrous oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-49.
18. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
19. Loscalzo J. N-acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985;76:703-8.
20. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 1996;79:363-80.
21. Brown BG, Bolson E, Petersen RB, Pierce CD, Dodge HT. The mechanisms of nitroglycerin action: stenosis vasodilatation as a major component of drug response. Circulation 1981;64:1089-97.
22. Goldstein RE, Stinson EB, Scherer JL, Seningen RP, Grehl TM, Epstein SE. Intraoperative coronary collateral function in patients with coronary occlusive disease: nitroglycerin responsivencss and angiographic correlations. Circulation 1974;49:298-308.
23. Fam WM, McGregor M. Effect of nitroglycerin and dipyridamole on regional coronary resistance. Circ Res 1968;22:649-59.
24. Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both: report of the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Br Heart J 1986;56:400-13.
25. Reichek N, Priest C, Chandler T, Bolton S, Laskey W, Sutton MS. Comparison of time of onset of hemodynamic effects of sustained-release buccal nitroglycerin and sublingual nitroglycerin. In: Goldberg AAJ, Parkson DG, eds. Modern concepts of nitrate delivery systems. London: Royal Society of Medicine, 1983:143-9.
26. Parker JO, Vankoughnett KA, Farrell B. Nitroglycerin lingual spray: clinical efficacy and dose-response relation. Am J Cardiol 1986;57:1-5.
27. Winsor T, Berger HJ. Oral nitroglycerin as a prophylactic antianginal drug: clinical, physiologic, and statistical evidence of efficacy based on a three-phase experimental design. Am Heart I 1975;90:611-26.
28. Reichek N, Goldstein RE, Redwood DR, Epstein SE. Sustained effects of nitroglycerin ointment in patients with angina pectoris. Circulation 1974;50:348-52.
29. Kala R, Hirvonen P, Gordin A, Sundberg S, Auvinen J, Halonen PL. Nitroglycerin ointment effective for seven hours in severe angina pectoris. Acta Med Scand 1983;213:165-70.
30. Reichek N, Priest C, Zimrin D, Chandler T, Sutton MS. Antianginal effects of nitroglycerin patches. Am J Cardiol 1984;54:1-7.
31. Parker JO, Fung H-L. Transdermal nitroglycerin in angina pectoris. Am J Cardiol 1984;54:471-6.
32. Steering Committee, Transdermal Nitroglycerin Cooperative Study. Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Am J Cardiol 1991;68:1263-73.
33. Cowan JC, Bourke JP, Reid DS, Julian DG. Prevention of tolerance to nitroglycerin patches by overnight removal. Am J Cardiol 1987;60:271-5.
34. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989;13:786-95.
35. Ferratini M, Pirelli S, Merlini P, Silva P, Pollavini G. Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: a comparison with a continuous schedule. Eur Heart J 1989;10:998-1002.
36. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris: clinically effective without tolerance or rebound: Minitran Efficacy Study Group. Circulation 1995;91: 1368-74.
37. Goldstein RE, Rosing DR, Redwood DR, Beiser GD, Epstein SE. Clinical and circulatory effects of isosorbide dinitrate: comparison with nitroglycerin. Circulation 1971;43:629-40.
38. Parker JO, Farrell B, Lahey KA, Moe G. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987;316:1440-4.
39. Bassan MM. The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate. J Am Coll Cardiol 1990;16:936-40.
40. Silber S, Vogler AC, Krause KH, Vogel M, Theisen K. Induction and circumvention of nitrate tolerance applying different dosage intervals. Am J Med 1987;83:860-70.
41. Kohli RS, Rodrigues EA, Kardash MM, Whittington JR, Raftery EB. Acute and sustained effects of isosorbide 5-mononitrate in stable angina pectoris. Am J Cardiol 1986;58:727-31.
42. Thadani U, Prasad R, Hamilton SF, et al. Usefulness of twice-daily isosorbide-5-mononitrate in preventing development of tolerance in angina pectoris. Am J Cardiol 1987;60:477-82.
43. Parker JO. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993;72:871-6.
44. Thadani U, Maranda CR, Amsterdam E, et al. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med 1994;120:353-9.
45. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993;72:1249-56.
46. Russek HI. Propranolol and isosorbide dinitrate synergism in angina pectoris. Am J Cardiol 1968;21:44-54.
47. Bassan MM, Weiler-Ravell D. The additive antianginal action of oral isosorbide dinitrate in patients receiving propranolol: magnitude and duration of effect. Chest 1983;83:233-40.
48. Battock DJ, Alvarez H, Chidsey CA. Effects of propranolol and isosorbide dinitrate on exercise performance and adrenergic activity in patients with angina pectoris. Circulation 1969;39:157-69.
49. Svendsen JH, Amtorp O. Mononitrates in combination with beta-blocker therapy in the treatment of severe angina pectoris. Drugs 1987;33: Suppl 4:122-4.
50. Boden WE, Bough EW, Reichman MJ, et al. Beneficial effects of high-dose diltiazem in patients with persistent effort angina on β-blockers and nitrates: a randomized, double-blind, placebo-controlled cross-over study. Circulation 1985;71:1197-205.
51. Meluzin J, Zeman K, Stetka F, Simek P. Effects of nifedipine and diltiazem on myocardial ischemia in patients with severe stable angina pectoris treated with nitrates and beta-blockers. J Cardiovasc Pharmacol 1992; 20:864-9.
52. Needleman P. Tolerance to the vascular effects of glyceryl trinitrate. J Pharmacol Exp Ther 1970;171:98-102.
53. Abdollah A, Moffat JA, Armstrong PW. N-acetylcysteine does not modify nitroglycerin-induced tolerance in canine vascular rings. J Cardiovasc Pharmacol 1987;9:445-50.
54. Fung HL, Chong S, Kowaluk E, Hough K, Kakemi M. Mechanisms for the pharmacologic interaction of organic nitrates with thiols: existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N-acetylcysteine. J Pharmacol Exp Ther 1988;245:524-30.
55. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923-31.
56. Parker JO, Parker JD. Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance. Am J Cardiol 1992;70:93B-97B.
57. Parker JD, Farrell B, Fenton T, Parker JO. Effects of diuretic therapy on the development of tolerance during continuous therapy with nitroglycerin. J Am Coll Cardiol 1992;20:616-22.
58. Parker JD, Parker JO. Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counterregulatory responses during continuous therapy with nitroglycerin. J Am Coll Cardiol 1993;21: 1445-53.
59. Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermal nitroglycerin therapy: decreased anginal threshold during the nitrate-free interval. Circulation 1995;91:973-8.
60. Packer M. What causes tolerance to nitroglycerin? The 100 year old mystery continues. J Am Coll Cardiol 1990;16:932-5.
61. Abrams J. Clinical aspects of nitrate tolerance. Eur Heart J 1991;12: Suppl E:42-52.
62. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 1991;114: 667-77.
63. Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther 1994;8:489-99.
64. Sutton SC, Fung H-L. Effect of dosage regimen on the development of tolerance to nitroglycerin in rats. J Cardiovasc Pharmacol 1983;5:1086-92.
65. Fung HL, Sutton SC, Kamiya A. Blood vessel uptake and metabolism of organic nitrates in the rat. J Pharmacol Exp Ther 1984;228:334-41.
66. Brien JF, McLaughlin BE, Kobus SM, Kawamoto JH, Nakatsu K, Marks GS. Mechanism of glyceryl trinitrate-induced vasodilation. I. Relationship between drug biotransformation, tissue cyclic GMP elevation and relaxation of rabbit aorta. J Pharmacol Exp Ther 1988;244:322-7.
67. Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol 1986;35:3525-31.
68. Axelsson KL, Andersson RG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol 1983;88:71-9.
69. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973;184:709-15.
70. Gruetter CA, Lemke SM. Effects of sulfhydryl reagents on nitroglycerin-induced relaxation of bovine coronary artery. Can J Physiol Pharmacol 1986;64:1395-401.
71. Boesgaard S, Aldershvile J, Poulsen HE, Loft S, Anderson ME, Meister A. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res 1994;74:115-20.
72. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
73. May DC, Popma JJ, Black WH, et al. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 1987; 317:805-9.
74. Horowitz JD, Antman EM, Lorell BH, Barry WH, Smith TW. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 1983;68:1247-53.
75. Winniford MD, Kennedy PL, Wells PJ, Hillis DL. Potentiation of nitroglycerin-induced coronary dilatation by N-acetylcysteine. Circulation 1986;73:138-42.
76. Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84:2336-45.
77. Katz RJ, Levy WS, Buff L, Wasserman AG. Prevention of nitrate tolerance with angiotension converting enzyme inhibitors. Circulation 1991; 83:1271-7.
78. Muiesan ML, Boni E, Castellano M, et al. Effects of transdermal nitroglycerin in combination with an ACE inhibitor in patients with chronic stable angina pectoris. Eur Heart J 1993;14:1701-8.
79. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995;95:187-94.
80. Münzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A 1995;92:5244-8.
81. Sussex BA, Campbell NRC, Raju MK, McKay DW. The antianginal efficacy of isosorbide dinitrate therapy is maintained during diuretic treatment. Clin Pharmacol Ther 1994;56:229-34.
82. Mohanty N, Wasserman AG, Walker P, Katz RJ. Prevention of nitroglycerin tolerance with diuretics. Am Heart J 1995;130:522-7.
83. Parker JD, Parker AB, Farrell B, Parker JO. The effects of diuretic therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina. Circulation 1996;93:691-6.
84. Yeates RA, Schmid M. Total prevention of the development of in vitro tolerance to organic nitrates: experiments with antioxidants. Arzneimittelforschung 1992;42:297-302.
85. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation 1997;96:2545-50.
86. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
87. Münzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest 1996;98:1465-70.
88. Cohn JN, Archibald DG, Zeische S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
89. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991;84:35-9.
90. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995;26:1575-80.
91. Parker JD, Parker AB, Farrell B, Parker JO. The effect of hydralazine on the development of tolerance to continuous nitroglycerin. J Pharmacol Exp Ther 1997;280:866-75.
92. Parker JO, Fung H-L, Ruggirello D, Stone JA. Tolerance to isosorbide dinitrate: rate of development and reversal. Circulation 1983;68:1074-80.
93. Lange RL, Reid MS, Tresch DD, Keelan MH, Bernhard VM, Coolidge G. Nonatheromatous ischemic heart disease following withdrawal from chronic industrial nitroglycerin exposure. Circulation 1972;46: 666-78.
94. Morton WE. Occupational habituation to aliphatic nitrates and the withdrawal hazards of coronary disease and hypertension. J Occup Med 1977;19:197-200.
95. Waters DD, Juneau M, Gossard D, Choquette G, Brien M. Limited usefulness of intermittent nitroglycerin patches in stable angina. J Am Coll Cardiol 1989;13:421-5.
96. Olsson G, Allgen J, Amtorp O, Nyberg G, Parker JO. Absence of predose rebound phenomena with once daily 5-ISMN in a controlled-release formulation. Eur Heart J 1992;13:814-7.
97. Münzel T, Bassenge E. Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation 1996;93:2052-8.